17 Sep Pharmacist-Led Medication Optimization Associated With 19.4% Lower Medical Costs in a Medicare ACO Population
Savings Increased With Duration of Program Exposure, Reaching 31.9% ($462 Per Member Per Month) Following a Nine-Month Implementation Window
INDIANAPOLIS, IN - September 15, 2026 (NEWMEDIAWIRE) - DecisionRx, Inc., a pharmacist-led medication optimization company, today announced findings from a new study of Medicare Accountable Care Organization (ACO) beneficiaries. The study found that when compared against matched controls, participation in the DecisionRx Medication Therapy Optimization (MTO) program was associated with a 19.4% reduction in total medical costs ($246 per member per month; p < 0.001). The intervention effect grew to 31.9% ($462 per member per month; p < 0.001) after 9 months of program exposure. Cost reductions were concentrated in acute and facility-based care.
Co-authored by DecisionRx executives in collaboration with researchers at the Johns Hopkins Bloomberg School of Public Health, the full study results, published online August 26, 2026 in Health Affairs Scholar, are available HERE.